Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally.
Mithra Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||€19.34|
|52 Week High||€14.92|
|52 Week Low||€28.95|
|1 Month Change||8.65%|
|3 Month Change||-0.72%|
|1 Year Change||14.44%|
|3 Year Change||-14.24%|
|5 Year Change||102.94%|
|Change since IPO||61.84%|
Recent News & Updates
Here's Why Mithra Pharmaceuticals (EBR:MITRA) Can Afford Some Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
When Will Mithra Pharmaceuticals SA (EBR:MITRA) Turn A Profit?
We feel now is a pretty good time to analyse Mithra Pharmaceuticals SA's ( EBR:MITRA ) business as it appears the...
|MITRA||BE Pharmaceuticals||BE Market|
Return vs Industry: MITRA exceeded the Belgian Pharmaceuticals industry which returned 13.9% over the past year.
Return vs Market: MITRA underperformed the Belgian Market which returned 23.1% over the past year.
Stable Share Price: MITRA is more volatile than 75% of Belgian stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: MITRA's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Belgian stocks.
About the Company
|1999||300||Leon Van Rompay||https://www.mithra.com|
Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally. Its development candidates include Estelle, which has completed phase III clinical trial, which is a combined oral contraceptive; Donesta, which is in phase III clinical trial for vasomotor menopausal symptoms relief; and PeriNesta, an oral treatment for perimenopause. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a solution for treating menopause and osteoporosis; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications.
Mithra Pharmaceuticals Fundamentals Summary
|MITRA fundamental statistics|
Is MITRA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MITRA income statement (TTM)|
|Cost of Revenue||€10.37m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-2.58|
|Net Profit Margin||-605.34%|
How did MITRA perform over the long term?See historical performance and comparison
Is Mithra Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: MITRA (€19.9) is trading above our estimate of fair value (€5.45)
Significantly Below Fair Value: MITRA is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: MITRA is unprofitable, so we can't compare its PE Ratio to the European Pharmaceuticals industry average.
PE vs Market: MITRA is unprofitable, so we can't compare its PE Ratio to the Belgian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MITRA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MITRA is overvalued based on its PB Ratio (8.9x) compared to the BE Pharmaceuticals industry average (3.1x).
How is Mithra Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MITRA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.2%).
Earnings vs Market: MITRA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MITRA's is expected to become profitable in the next 3 years.
Revenue vs Market: MITRA's revenue (72.8% per year) is forecast to grow faster than the Belgian market (6.7% per year).
High Growth Revenue: MITRA's revenue (72.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MITRA's Return on Equity is forecast to be very high in 3 years time (49.5%).
How has Mithra Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MITRA is currently unprofitable.
Growing Profit Margin: MITRA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MITRA is unprofitable, and losses have increased over the past 5 years at a rate of 16.1% per year.
Accelerating Growth: Unable to compare MITRA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MITRA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10.2%).
Return on Equity
High ROE: MITRA has a negative Return on Equity (-115.2%), as it is currently unprofitable.
How is Mithra Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: MITRA's short term assets (€121.8M) exceed its short term liabilities (€47.1M).
Long Term Liabilities: MITRA's short term assets (€121.8M) do not cover its long term liabilities (€291.4M).
Debt to Equity History and Analysis
Debt Level: MITRA's debt to equity ratio (268.3%) is considered high.
Reducing Debt: MITRA's debt to equity ratio has increased from 43.4% to 268.3% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MITRA has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if MITRA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Mithra Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MITRA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MITRA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MITRA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MITRA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: MITRA is not paying a notable dividend for the Belgian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MITRA's dividend in 3 years as they are not forecast to pay a notable one for the Belgian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Leon Van Rompay
Mr. Leon Van Rompay serves as Interim Chief Executive Officer at Mithra Pharmaceuticals SA since February 2021. He founded Docpharma BVBA and serves as its Chief Executive of Docpharma BVBA. Mr. Van Rompay...
Experienced Management: MITRA's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.4%.
Mithra Pharmaceuticals SA's employee growth, exchange listings and data sources
- Name: Mithra Pharmaceuticals SA
- Ticker: MITRA
- Exchange: ENXTBR
- Founded: 1999
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: €870.368m
- Shares outstanding: 43.74m
- Website: https://www.mithra.com
Number of Employees
- Mithra Pharmaceuticals SA
- Rue Saint-Georges 5
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/25 17:55|
|End of Day Share Price||2021/10/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.